ARIAD Pharmaceuticals ( ARIA ): Q1 EPS of -$0.35 misses by $0.12 . Revenue of $81K (+33.3% Y/Y) misses by $219K . Shares +0.3% premarket. ( PR ) Post your comment!
… before trading. Use this list as a potential starting point for your analysis. 1. Ariad Pharmaceuticals ( ARIA ) -- Key Date: June 5, 2012 Ariad Pharmaceuticals , an oncology company, focuses on the discovery, development, and commercialization …
… other side are the companies which much more certain prospects, but considerably higher valuations. With Ariad Pharmaceuticals ' ( ARIA ) stock already incorporating some pretty big things, investors have to ask how much more than can expect …
Oppenheimer agrees with Jefferies analysis of Ariad Pharmaceuticals ( ARIA +2.4% ), saying the stock should be bought on any Taltorvic-related weakness. The firm notes the drug accounts for just …
(Reuters) - Ariad Pharmaceuticals ' shares fell 3 percent on Wednesday morning after a U.S. Food and Drug Administration panel did not recommend the company's experimental cancer candidate.
WASHINGTON, March 20 (Reuters) - A Food and Drug Administration panel on Tuesday chose not to recommend a drug developed by Merck & Co Inc and Ariad Pharmaceuticals Inc for maintenance treatmement...
A FDA panel questions the risks and side effects of a drug developed by Ariad Pharmaceuticals ( ARIA ) and Merck ( MRK ) to treat sarcoma. Shares of ARIA -1.9% premarket, MRK inactive. Post your comment!
Ariad Pharmaceuticals ( ARIA ): Q4 EPS of -$0.38 misses by $0.18 . Revenue of $78M (+44.4% Y/Y). Shares +0.9% premarket. ( PR ) Post your comment!
By Scott Matusow : Ariad Pharmaceuticals ( ARIA ) is a biopharmaceutical company focusing on the discovery, development and commercialization of small-molecule drugs for the …
Ariad Pharmaceuticals ( ARIA +5.4% ) gains after announcing pricing on its common stock offering . A total of 21.5M shares will be priced to the public at $10.42/share in a deal expected to close on or about Dec. 20. Post your comment!